AU
UK
CA
NZ
IND
US
A Constructive Update for a High-Need Liver Disease Program
Regulatory Progress Brings Renewed Attention
Capital Raise Followed by Immediate Equity Conversion
Clinical Expansion Supports Global Hepatitis B Ambitions
Regulatory Momentum Builds for Arbutus
Capital Raise Prioritizes Pipeline Continuity
New Endocrine Data Strengthens Development Case
Shares of Taysha Gene Therapies climbed 15 per cent on Wednesday after Canaccord Genuity raised its price target on the stock to $17 from $14, a move that reflects mounting analyst confidence in the Dallas-based company's clinical trajectory and the broadening commercial potential of …
Key Highlights
Key Highlights
Please wait processing your request...